Evidence map›Paper›PMID 41275032›Full record

SynthesisCardiovascular intervention and therapeutics2026

Network meta-analysis of treatment strategies for calcified coronary lesions.

Michele Maremmani, Gabriele Gasparini, Francesco Bruno, Sergio Berti, Simonluca Digiacomo, Ramin Ebrahimi, Christian Templin, Paolo Canova, Gabriele Pesarini, Davide Di Vece

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Michele MaremmaniDepartment of Cardiology, Pio XI Hospital, Via Giuseppe Mazzini 1, Desio, 20832, Italy. michelemaremmani.90@gmail.com.ORCID http://orcid.org/0000-0002-6510-4025
Gabriele GaspariniDepartment of Invasive Cardiology, Humanitas Clinical and Research Center, IRCCS, Rozzano, Italy.
Francesco BrunoDivision of Cardiology, Department of Medical Sciences, AOU Città della Salute e della Scienza, University of Turin, Turin, Italy.
Sergio BertiFondazione Toscana Gabriele Monasterio, Massa, Italy.
Simonluca DigiacomoDepartment of Cardiology, Ospedale Maggiore, Crema, Italy.
Ramin EbrahimiDepartment of Internal Medicine B, University of Medicine Greifswald, Greifswald, Germany.
Christian TemplinDepartment of Internal Medicine B, University of Medicine Greifswald, Greifswald, Germany.
Paolo CanovaCardiovascular Department, Ospedale Papa Giovanni XXIII, Bergamo, Italy.
Gabriele PesariniDivision of Cardiology, Department of Medicine, University of Verona, Verona, Italy.
Davide Di VeceDepartment of Internal Medicine B, University of Medicine Greifswald, Greifswald, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Comparative evidence on treatment strategies for calcified coronary lesions (CCL) remains scarce, with few head-to-head trials and limited data on clinical outcomes. We conducted a frequentist network meta-analysis of randomized controlled trials (RCTs) comparing excimer laser (ELCA), lithotripsy (IVL), modified balloons (MBA), orbital atherectomy (OA), rotational atherectomy (RA), and RA plus cutting balloons (RA plus CBA) against a conventional strategy (CS). The primary endpoints were severe adverse events (SAE: death, coronary perforation, or slow-flow/no-reflow) and minimum stent area (MSA), while secondary endpoints included major adverse cardiovascular events (MACE) and target lesion revascularization (TLR). Fourteen RCTs including 3,671 patients were analyzed. Atherectomy-based strategies carried a higher risk of SAE versus CS, driven by slow-flow/no-reflow phenomenon. All strategies except OA and ELCA significantly increased MSA compared with CS, with the largest effect observed for RA plus CBA (MD 0.93 mm²; 95% CI 0.48-1.38). None of the strategies reduced MACE or TLR versus CS, although RA plus CBA ranked highest for both endpoints. IVL improved MSA (MD 0.59 mm²; 95% CI 0.14-1.03) without increasing SAE and ranked favorably for MACE and TLR, with the highest probability of lower mortality. Stand-alone MBA remained low-ranked for TLR, and sensitivity analysis confirmed its inferior MSA performance versus IVL. In summary, upfront plaque-modification improved MSA compared with a conventional strategy, although this gain did not translate into significant reductions in MACE or TLR, likely reflecting the limited number of events. RA plus CBA had the highest likelihood of lower MACE and TLR despite higher procedural risk, whereas IVL provided the most favorable balance between safety and efficacy.

Indexed as

Atherectomy, CoronaryCoronary Artery DiseaseVascular CalcificationHumansLithotripsyNetwork Meta-Analysis as TopicRandomized Controlled Trials as TopicAtherectomyCalcified coronary lesionsIntravascular lithotripsyLesion preparationNetwork meta-analysis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.